9th Jun 2016 14:58
9 June 2016
LSE: VER
Vernalis Plc ("Vernalis" or the "Company")
Directors Dealing
The Company has today received notification that, on 9 June 2016, the following Directors of the Company purchased ordinary shares of 1 pence each in the Company ("Ordinary Shares"), as set out below:
Director Name | Number of Ordinary Shares Purchased | Price per Ordinary Share | Resulting Beneficial Holding, Ordinary Shares | Holding as a Percentage of Company's Issued Share Capital |
Ian Garland, CEO | 245,000 | £0.45 | 1,049,857 | 0.20% |
David Mackney, CFO | 97,000 | £0.45 | 512,203 | 0.10% |
-- ends --
Enquiries:
Vernalis plc: | +44 (0) 118 938 0015 |
Ian Garland, Chief Executive Officer | |
David Mackney, Chief Financial Officer
| |
Canaccord Genuity Limited (Nominated Adviser): | +44 (0) 20 7523 8000 |
Dr Julian Feneley | |
Rupert Winckler | |
Henry Fitzgerald-O'Connor | |
Emma Gabriel
| |
Shore Capital (Joint Broker): | +44 (0)20 7408 4090 |
Bidhi Bhoma | |
Toby Gibbs
| |
FTI Consulting: | +44 (0) 20 3727 1000 |
Ben Atwell | |
Simon Conway | |
Stephanie Cuthbert
|
Notes to Editors
About Vernalis
Vernalis is a revenue generating, commercial stage pharmaceutical company with significant expertise in drug development. The Group has three approved products: Tuzistra® XR targeting the US prescription cough-cold market; Moxatag®, a once-a-day formulation of the antibiotic, amoxicillin, indicated for the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes in adults and pediatric patients 12 years and older; and frovatriptan for the acute treatment of migraine. It has an exclusive licensing agreement to develop and commercialise multiple novel products focussed on the US prescription cough-cold market as well as eight programmes in its NCE development pipeline. Vernalis has also significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including Asahi Kasei Pharma, Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier, Taisho, and Tris.
For further information about Vernalis, please visit www.vernalis.com.
Related Shares:
Vernalis PLC